tiprankstipranks
Trending News
More News >
Bio-Gene Technology Ltd. (AU:BGT)
ASX:BGT
Australian Market

Bio-Gene Technology Ltd. (BGT) AI Stock Analysis

Compare
6 Followers

Top Page

AU

Bio-Gene Technology Ltd.

(Sydney:BGT)

Rating:42Neutral
Price Target:
Bio-Gene Technology Ltd. struggles with significant financial challenges and weak technical indicators, resulting in a low overall score. The absence of earnings and a negative P/E ratio further affect its valuation negatively. The company's debt-free balance sheet is a positive aspect but insufficient to offset the overall negative outlook.

Bio-Gene Technology Ltd. (BGT) vs. iShares MSCI Australia ETF (EWA)

Bio-Gene Technology Ltd. Business Overview & Revenue Model

Company DescriptionBio-Gene Technology Ltd. (BGT) is an innovative biotechnology company focused on the research and development of novel pest control technologies. Operating primarily in the agricultural and public health sectors, BGT aims to provide sustainable and environmentally friendly solutions to pest management challenges. The company's core products are based on proprietary technology, which leverages natural compounds to offer alternatives to traditional chemical pesticides.
How the Company Makes MoneyBio-Gene Technology Ltd. generates revenue through the commercialization of its proprietary pest control technologies. The company's primary revenue streams include licensing agreements with agricultural and chemical companies that incorporate BGT's technology into their own product lines. Additionally, BGT engages in strategic partnerships to co-develop and distribute its products, allowing for shared revenue and expanded market reach. The company may also receive funding through grants and research collaborations aimed at advancing its technology and expanding its application areas. Sales of its own branded products, if applicable, would also contribute to its earnings.

Bio-Gene Technology Ltd. Financial Statement Overview

Summary
Bio-Gene Technology Ltd. is facing financial challenges with declining revenues, persistent losses, and negative cash flows. Despite these issues, the company benefits from a debt-free balance sheet, providing some financial stability.
Income Statement
35
Negative
Bio-Gene Technology Ltd. shows a declining revenue trend over the years, with a significant drop in revenue from 2023 to 2024. The company has consistently reported negative net income, indicating persistent losses. The gross profit margin is negative, reflecting challenges in covering the cost of goods sold. Additionally, negative EBIT and EBITDA margins point to inefficiencies in operations and high operating expenses relative to revenue.
Balance Sheet
60
Neutral
The company's balance sheet reveals a strong equity position with no debt, resulting in a favorable debt-to-equity ratio of zero. The equity ratio remains high, indicating stability in financial structure. However, declining stockholders' equity and total assets over the years suggest a weakening financial position. The return on equity is negative due to the consistent net losses.
Cash Flow
40
Negative
Cash flow analysis shows consistent negative operating cash flows, indicating challenges in generating cash from core operations. The free cash flow has also been negative, suggesting insufficient cash flow to cover capital expenditures without external financing. The operating cash flow to net income ratio is negative, highlighting the gap between reported earnings and cash flow generation.
BreakdownTTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue-435.0018.32K595.08K879.78K573.12K907.58K
Gross Profit-558.91K-301.45K281.80K612.64K399.92K640.45K
EBITDA-2.41M-2.97M-3.14M-2.92M-2.39M-2.05M
Net Income-2.36M-2.41M-3.10M-2.80M-2.36M-1.87M
Balance Sheet
Total Assets1.87M3.16M3.84M7.30M5.00M6.57M
Cash, Cash Equivalents and Short-Term Investments1.34M2.21M2.99M6.34M3.93M5.52M
Total Debt0.000.000.000.000.0011.66K
Total Liabilities541.70K368.45K613.88K1.03M754.57K567.29K
Stockholders Equity1.33M2.79M3.22M6.27M4.25M6.00M
Cash Flow
Free Cash Flow-1.88M-2.76M-3.28M36.67K-1.83M-1.64M
Operating Cash Flow-1.88M-2.75M-3.28M43.52K-1.83M-1.64M
Investing Cash Flow0.00-5.70K0.00-6.84K-3.03K0.00
Financing Cash Flow0.001.98M-75.00K4.41M239.88K2.67M

Bio-Gene Technology Ltd. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.02
Price Trends
50DMA
0.02
Negative
100DMA
0.03
Negative
200DMA
0.04
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
38.08
Neutral
STOCH
122.22
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BGT, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.04, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 38.08 is Neutral, neither overbought nor oversold. The STOCH value of 122.22 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:BGT.

Bio-Gene Technology Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AUNAN
73
Outperform
$1.17B70.519.23%10.79%5.20%
AUTLX
69
Neutral
$8.19B160.2014.52%55.85%893.42%
AUCYC
49
Neutral
AU$123.92M-35.20%4.68%-155.42%
49
Neutral
AU$2.50B4.42-64.25%2.77%36.51%13.14%
AUBGT
42
Neutral
AU$5.06M
AUIMU
40
Underperform
$93.34M-99.05%-33.99%
AUOPT
30
Underperform
$738.77M
-24.46%-7.90%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:BGT
Bio-Gene Technology Ltd.
0.02
-0.03
-60.00%
AU:OPT
Opthea
0.60
0.24
66.67%
AU:TLX
Telix Pharmaceuticals
24.05
6.05
33.61%
AU:IMU
Imugene
0.41
-1.29
-75.88%
AU:NAN
Nanosonics Limited
3.91
0.93
31.21%
AU:CYC
Cyclopharm Limited
1.12
-0.56
-33.33%

Bio-Gene Technology Ltd. Corporate Events

Bio-Gene Technology Ltd Updates Securities Issue Announcement
May 5, 2025

Bio-Gene Technology Ltd announced a correction to a previous statement regarding the proposed issue of securities. This update, which addresses a typographic error, pertains to the company’s plans to offer securities under a securities purchase plan. The correction ensures clarity in the company’s communication with stakeholders and aligns with ASX listing rules, potentially impacting investor confidence and market positioning.

Bio-Gene Technology Announces Proposed Securities Issue to Boost Market Position
May 5, 2025

Bio-Gene Technology Ltd has announced a proposed issue of securities, including unlisted options and ordinary fully paid shares, as part of a securities purchase plan and placement. This move is expected to enhance the company’s financial position, potentially enabling further development of its insecticide products and strengthening its market presence.

Bio-Gene Technology Advances in Nature-Derived Insecticides
May 5, 2025

Bio-Gene Technology Ltd. presented an investor update highlighting its progress in developing nature-derived insecticides. This initiative is expected to enhance the company’s market positioning by offering sustainable solutions to pest control, potentially impacting stakeholders positively by addressing global insecticide needs.

Bio-Gene Technology Secures $2.1 Million for Key Insecticide Development
May 5, 2025

Bio-Gene Technology Ltd announced a successful capital raise of $2.1 million through a placement with sophisticated investors and plans to offer a Share Purchase Plan to eligible shareholders. The funds will be used to conduct regulatory-enabling safety studies for Flavocide®, a key step towards its approval in Australia, and to support the scale-up of Qcide, product development, and strategic projects. This financial boost is expected to significantly advance Bio-Gene’s operational capabilities and strengthen its position in the pest control industry.

Bio-Gene Technology Showcases Innovations at NWR Virtual Healthcare Conference 2025
Mar 19, 2025

Bio-Gene Technology Limited announced its participation in the NWR Virtual Healthcare Conference 2025, where CEO Tim Grogan will present the company’s advancements in bio-insecticides. This presentation highlights Bio-Gene’s commitment to addressing insecticide resistance and toxicity issues, potentially enhancing its market position and offering stakeholders innovative solutions for pest management.

Bio-Gene Technology to Present at NWR Virtual Healthcare Conference
Mar 16, 2025

Bio-Gene Technology Limited announced its participation in the NWR Virtual Healthcare Conference, where CEO Tim Grogan will present on the company’s innovative insecticide solutions. This presentation highlights Bio-Gene’s commitment to addressing pest control challenges and could enhance its visibility and positioning in the bio-insecticide industry, potentially impacting stakeholders by showcasing its environmentally friendly and effective products.

Bio-Gene Technology Advances Insecticide Development and Strengthens IP Portfolio
Feb 27, 2025

Bio-Gene Technology Limited reported several key achievements for the six months ending December 2024, including a collaboration with Envu to develop Flavocide® for mosquito management, successful pilot-scale production of Flavocide, and the initiation of safety studies in Europe and India. The company also completed its thirteenth Qcide® harvest, improved seed and seedling production, and expanded formulation development programs. Additionally, Bio-Gene strengthened its intellectual property portfolio with six new patents and five new applications, positioning itself strongly in the bio-insecticide market.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 22, 2025